Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
Victoria McCreanorAlexandra N NowbarChristopher RajkumarAdrian Gerard BarnettDarrel FrancisNicholas GravesWilliam E BodenWilliam S WeintraubRasha Al-LameeWilliam A ParsonagePublished in: BMJ open (2021)
The ICER for PCI compared with placebo, in patients with single-vessel coronary artery disease and angina on anti-anginal medication, exceeds the threshold of £30 000 used by the National Institute of Health and Care Excellence when undertaking health technology assessment for the NHS context.Trial registration: The ORBITA study is registered with ClinicalTrials.gov, number NCT02062593.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- healthcare
- st segment elevation myocardial infarction
- phase iii
- coronary artery bypass grafting
- antiplatelet therapy
- st elevation myocardial infarction
- cardiovascular events
- public health
- acute myocardial infarction
- study protocol
- acute coronary syndrome
- clinical trial
- phase ii
- quality improvement
- mental health
- health information
- health promotion
- patient safety
- palliative care
- coronary artery bypass
- double blind
- type diabetes
- heart failure
- randomized controlled trial
- human health
- chronic pain
- risk assessment
- placebo controlled
- atrial fibrillation
- climate change